Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Delta Oxy Bolus is a veterinary combination medication developed by Wayzon Pharma, containing the broad-spectrum antibiotic oxytetracycline and the synthetic corticosteroid dexamethasone. Oxytetracycline exerts its antibacterial effect by binding to the 30S ribosomal subunit of susceptible bacteria, thereby inhibiting protein synthesis. It is active against a wide range of Gram-positive and Gram-negative bacteria, as well as Rickettsia and Mycoplasma. Dexamethasone provides potent anti-inflammatory and anti-stress activity by acting as an agonist at the glucocorticoid receptor. This combination is specifically formulated for livestock to treat systemic and local infections, such as pneumonia, metritis, and hemorrhagic septicemia, where the reduction of associated inflammation and toxemia is clinically beneficial for recovery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxytetracycline + dexamethasone.